Overexpression of flotillin-1 is involved in proliferation and recurrence of bladder transitional cell carcinoma

YAWEI GUAN¹, HAIYAN SONG², GUOHUI ZHANG¹ and XING AI¹

¹Department of Urinary Surgery, Beijing Military Region General Hospital, Beijing 100700;
²Department of Blood Transfusion, The 309th Hospital of Chinese PLA, Beijing 100091, P.R. China

Received March 19, 2014; Accepted May 2, 2014
DOI: 10.3892/or.2014.3221

Abstract. Flotillin-1 (FLOT1) is known to have a role in tumorigenesis; however, the effect of FLOT1 on proliferation and recurrence of human transitional cell carcinoma (TCC) is unclear. Samples from 156 TCC patients and 142 patients undergoing open bladder surgery for indications other than TCC were used in the present study. FLOT1 protein expression was determined by immunohistochemistry and western blot analysis, and mRNA expression was detected by RT-PCR and real-time PCR. A FLOT1-expressing pcDEF3 vector was stably transfected into 4 TCC cell lines and FLOT1 expression was decreased by RNAi. Proliferative analysis of TCC cells was detected by the WST-1 assay and a xenograft model using BALB/C nude mice. The association between FLOT1 expression and TCC recurrence was also analyzed by adhesion, migration and invasion assays. FLOT1 expression in TCC was significantly upregulated compared to normal urothelial tissue, and the level of FLOT1 expression was significantly correlated with tumor size, pathologic grade, clinical stage and recurrence. In addition, FLOT1 significantly increased the proliferative ability of TCC cells in vitro and in vivo. TCC cells with a high level of FLOT1 expression exhibited a higher level of adhesion, migration and invasion. FLOT1 expression was shown to be upregulated in human TCC. These findings suggest that FLOT1 plays an important role in the proliferation and recurrence of TCC and that silencing FLOT1 expression might be a novel therapeutic strategy.

Introduction

Bladder carcinoma is a common malignancy worldwide, and is associated with a high morbidity and mortality (1). Approximately 90% of bladder carcinomas are transitional cell carcinomas (TCCs); 70-80% of TCCs are non-muscle-invasive (pTa-pT1) and 20-30% of TCCs are muscle-invasive (pT2-pT4). Moreover, 50-70% of these non-muscle-invasive TCCs will recur and 10-30% will become muscle-invasive TCCs (2). The prognosis of TCCs mainly depends on the clinical stage and histologic grade of the tumor at the time of diagnosis (3). The 5-year overall survival rate for non-muscle-invasive TCCs is 90%, and 60, 35 and 25% for pT2, pT3 and pT4 TCCs, respectively (4,5). Despite the advances in treatment and surveillance strategies, the mortality rate amongst patients with TCCs is on the rise, as is the tumor recurrence rate. Thus, the mechanisms underlying TCC recurrence also require elucidation, and studies seeking to further understand TCC recurrences are necessary for the development of novel approaches and improved therapeutic strategies.

The dynamic structure of the cell membrane usually plays a vital role in some biological processes, such as cell growth, survival and metastasis. Lipid rafts have been reported to be associated with the development of a number of malignancies (6,7) and serve as a physical platform on which molecules coordinate signaling pathways (8-10). Therefore, it has been demonstrated that lipid rafts may be a distinctive therapeutic target and treatment strategy to overcome malignant cancers (11,12). Flotillin-1 (FLOT1) and FLOT2 are homologous isoforms of the flotillin protein family and are essential markers of lipid rafts (13-15). FLOT1 and FLOT2 interact with each other to form a complex and have an important role in biological processes, such as membrane receptor signaling, membrane trafficking, cell adhesion and invasion (16). Increased activation of Fyn kinase leads to the translocation of FLOT1 and FLOT2 from the membrane to intracellular organelles, and participates in tyrosine kinase-regulated endocytic processes (17). FLOT1 and FLOT2 have been reported to activate signaling pathways via binding to membrane receptor kinases; for example, stimulation with insulin can prompt the complex formation of Cbl-CAP and FLOT1, which launches signal conduction that is important for the uptake of glucose in adipocytes (18). Previous studies have indicated that FLOT1 and FLOT2 are also involved in tumorigenesis and progression of human carcinomas (19,20). FLOT1 expression has been reported to be upregulated in carcinomas of epithelial origin, such as colorectal carcinomas and esophageal squamous cell carcinomas (21,22). Moreover, overexpression of FLOT1 enhances the activity of Aurora B kinase and leads to incorrect attachment of microtubules to
kinetochores, suggesting that FLOT1 can cause genomic instability and may be associated with tumorigenesis (23). In another study, overexpression of FLOT1 was also observed and prompted proliferation of prostate cancer cells (24). These findings suggest that FLOT1 may play an important role in the progression and development of malignant carcinomas; however, the expression of FLOT1 has not been reported and the role of FLOT1 in human TCC remains unclear.

In the present study, we determined the expression of FLOT1 and its effect on the proliferation and recurrence of human TCC. Our results suggest that FLOT1 expression is upregulated in TCC and that FLOT1 can enhance the proliferation of TCC cells in vitro and in vivo. Thus, FLOT1 may serve as a therapeutic target for TCC. Moreover, FLOT1 increased the adhesion, migration and invasion of TCC cells, suggesting that FLOT1 may be involved in TCC recurrence and that FLOT1 may be a candidate marker for predicting TCC recurrence.

Materials and methods

Patients and samples. The study included 156 TCC patients treated in the Department of Urology of Beijing Military Region General Hospital between 2001 and 2011. No patients received radiotherapy or chemotherapy before surgery. The histologic cell type of the bladder cancer samples was evaluated by an experienced pathologist without prior knowledge of the patient disease data; all tumors in the present study were conventional TCC. Normal urothelial tissues were also obtained from 142 patients undergoing open bladder surgery for indications other than TCC, such as benign prostatic hyperplasia and trauma. Tumor stage was classified according to the UICC 2009 TNM classification system, and the histologic grade was assessed according to the WHO 2004 grading system of TCC. All TCC samples and normal bladder tissues were obtained, formalin-fixed and paraffin-embedded. In addition, all samples in the present study were also frozen in liquid nitrogen immediately after surgical resection, and kept at -90°C until total RNA and protein extraction. The study was approved by the Ethics Committee of the Beijing Military Region General Hospital.

Cell culture. Four TCC cell lines (RT112, 253J, T24 and TCCSUP) were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA) and cultured in complete medium, consisting of RPMI-1640 (Gibco Bio-Cult, Glasgow, Scotland), supplemented with 25 mM HEPES, 2 mM L-glutamine, 100 U/ml of penicillin or 100 µg/ml of streptomycin, 10% heat-inactivated fetal bovine serum (FBS), and 1% non-essential amino acids. All TCC cell lines were maintained as monolayers in 10-cm plastic dishes and cultured in a humidified atmosphere containing 5% CO2 at 37°C.

Immunohistochemistry. Paraffin sections (4 µm) were deparaffinized in xylene and rehydrated with graded alcohol. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 20 min. All sections were also blocked with 20% rabbit serum for 30 min prior to a 2-h incubation with primary antibody. FLOT1 monoclonal antibody was purchased from Cell Signaling Technology. The sections were washed twice with Tris-buffered saline, then incubated with biotinylated anti-rabbit antibody (Dako, Glostrup, Denmark). Analysis of the antibody reaction was performed with a streptavidin-biotin complex, and the results of immunohistochemistry were detected using a light microscope. FLOT1 immunostaining was semi-quantitatively evaluated for intensity (-, negative; +, weak; ++, moderate; and +++, strong).

RT-PCR and real-time PCR. Messenger RNA was extracted from normal bladder and TCC tissues using a Quick Prep mRNA Purification kit (GE Healthcare, Buckinghamshire, UK) according to the manufacturer's instructions. A First-Strand cDNA Synthesis kit (Amersham Biosciences, Little Chalfont, UK) was used for reverse transcription. The PCR was carried out according to the manufacturer's instructions, and the PCR products were examined by agarose gel electrophoresis. Real-time PCR was performed using LC FastStart DNA Master SYBR-Green I (Roche, Carlsbad, CA, USA) and the PCR products were quantified with a LightCycler (Roche). The primers for FLOT1 were: forward, 5'-CCATCTCGTCAC TGGCAAT-3'and reverse, 5'-CGCAAATCTCCTTGTTC-3'. The GAPDH (internal control) primer sequences were: forward, 5'-TCAAGAAGGTGGTAAGCAGG-3' and reverse 5'-GTGGAGAGTGTTGCGG-3'.

Western blot analysis. Western blot analysis was carried out according to the manufacturer's instructions. Total protein was isolated and the protein concentration was measured, then SDS polyacrylamide gel electrophoresis was performed. Antibody to FLOT1 was purchased from Cell Signaling Technology, and an anti-β-actin monoclonal antibody (Abcam, Cambridge, UK) was used as an internal control. The immune complexes were determined using an ECL system (Amersham, Aylesbury, UK).

RNAi and transfection. All siRNA oligonucleotide sequences were designed using the siDirect software. TCC cells were seeded in culture dishes with complete medium without antibiotics until the confluence reached 50-60%. Then, TCC cells were transfected with siRNA oligonucleotides using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). After incubation for 2 days, FLOT1 protein expression was determined by western blot analysis. The cDNA coding sequence of FLOT1 was cloned by RT-PCR from normal human bladder tissue as a substrate, and the PCR products were subcloned into a pcDEF3 vector. Then, the 4 TCC cell lines were stably transfected with pcDEF3 vector containing full-length cDNA for FLOT1 using Lipofectamine 2000. The TCC monoclonal cell lines were selected with G418 and FLOT1 protein expression was confirmed by western blot analysis.

Proliferation analysis in vitro. The effect of FLOT1 on the proliferation of TCC cells was investigated using the WST-1 assay. Exponentially growing TCC cells (4x103) were harvested and seeded in 96-well microtiter plates. After continuous incubation for 1-3 days, 10 µl of WST-1 (Roche Diagnostics GmbH, Penzberg, Germany) was added to each well and the incubation was continued for an additional 2 h. The absorbance of each well, representing the cell count, was detected with a microculture plate reader (Immunoreader: Japan Intermed Co., Ltd., Tokyo, Japan) at 450 nm.
and 19 were classified as grades I, II and III according to the 2004 WHO classification, respectively. The clinical stage was reviewed based on the UICC 2009 TNM staging system; 51, 46, 37 and 22 were stages T1, T2, T3 and T4, respectively (Table I). The follow-up period was 22-64 months. Presenting symptoms included hematuria (124 patients), abdominal pain (32 patients), urinary discomfort (86 patients) and palpable masses (6 patients). Ten patients had metastatic disease at the time of diagnosis; anemia existed in 38 patients and 32 patients had >2 concomitant diseases (angina pectoris, diabetes mellitus and urolithiasis).

Flot1 expression in TCCs by IHC. Flot1 protein expression in human TCCs and normal urothelial tissues was detected by immunohistochemistry. The expression of Flot1 in TCC was significantly overexpressed compared to normal urothelial tissue (Fig. 1). Specifically, Flot1 expression was detected in 145/156 TCCs (92.9%); 44.1% of TCCs had moderate and strong Flot1 expression. Flot1 expression was only detected in 17/142 normal urothelial tissues (12%); 23.5% of normal urothelial tissues had moderate and strong Flot1 expression. The level of Flot1 expression was significantly related to tumor size, pathologic grade, clinical stage and recurrence based on χ² statistics (P≤0.05). In contrast, none of the other variables, such as gender and age, had a significant association with Flot1 expression (Table I). These findings suggest that Flot1 may be involved in tumorigenesis in human TCC.

Flot1 expression in TCC by RT-PCR, real-time PCR and western blot analysis. Flot1 expression in human TCCs and normal urothelial tissues was confirmed by RT-PCR, real-time PCR and western blot analysis. The relative level of Flot1 expression was calculated as the ratio to the internal control. The results suggested that Flot1 expression was upregulated significantly in TCCs compared to normal urothelial tissue, and the level of Flot1 expression was similar to the levels detected by immunohistochemistry. Moreover, Flot1 expression was significantly associated with tumor size, pathologic grade, clinical stage and recurrence based on t-tests (P≤0.05). The results of representative samples are shown in Fig. 2.

Flot1 enhances the proliferation of TCC. An expression pcDEF3 vector containing the full-length cDNA for Flot1 was stably transfected into 4 TCC cell lines (RT112, 253J, T24 and TCCSUP). In addition, Flot1 expression was also decreased using RNAi. All transfected cell lines were confirmed by western blot analysis, and Flot1 expression was significantly increased by the Flot1 vector insert and decreased by siRNA (Fig. 3A). The effect of Flot1 expression on the proliferation of TCC cells in vitro was evaluated by the WST-1 assay. TCC cells expressing high Flot1 exhibited significantly increased proliferative ability compared to control cells; however, TCC cells with low Flot1 expression had a lower proliferative ability (Fig. 3B). Moreover, similar results were also confirmed in vivo using an animal xenograft model with BALB/C nude mice (Fig. 3C). These findings suggested that Flot1 may be involved in proliferation of human TCC.
Table I. FLOT1 expression and characteristics of patients with TCC investigated by immunohistochemistry and real-time PCR.

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>FLOT1 mRNA (mean ± SD)</th>
<th>P-value</th>
<th>FLOT1 protein</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>TCC</td>
<td>156</td>
<td>2.31±0.35</td>
<td>&lt;0.05</td>
<td>15</td>
<td>77</td>
</tr>
<tr>
<td>Normal bladder tissue</td>
<td>142</td>
<td>0.71±0.22</td>
<td></td>
<td>125</td>
<td>13</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>75</td>
<td>2.34±0.29</td>
<td>&gt;0.05</td>
<td>7</td>
<td>37</td>
</tr>
<tr>
<td>Female</td>
<td>81</td>
<td>2.29±0.27</td>
<td>&gt;0.05</td>
<td>8</td>
<td>40</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60</td>
<td>95</td>
<td>2.28±0.26</td>
<td>&gt;0.05</td>
<td>9</td>
<td>45</td>
</tr>
<tr>
<td>≥60</td>
<td>61</td>
<td>2.36±0.33</td>
<td>&gt;0.05</td>
<td>6</td>
<td>32</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;3</td>
<td>103</td>
<td>1.51±0.18</td>
<td>&lt;0.05</td>
<td>10</td>
<td>58</td>
</tr>
<tr>
<td>≥3</td>
<td>53</td>
<td>3.86±0.55</td>
<td>&lt;0.05</td>
<td>5</td>
<td>19</td>
</tr>
<tr>
<td>Histologic grade</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>89</td>
<td>1.31±0.19</td>
<td>&lt;0.05</td>
<td>12</td>
<td>60</td>
</tr>
<tr>
<td>II</td>
<td>48</td>
<td>3.12±0.34</td>
<td>&lt;0.05</td>
<td>3</td>
<td>17</td>
</tr>
<tr>
<td>III</td>
<td>19</td>
<td>4.95±0.46</td>
<td>&lt;0.05</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1-T2</td>
<td>97</td>
<td>1.42±0.23</td>
<td>&lt;0.05</td>
<td>10</td>
<td>65</td>
</tr>
<tr>
<td>T3-T4</td>
<td>59</td>
<td>3.77±0.36</td>
<td>&lt;0.05</td>
<td>5</td>
<td>12</td>
</tr>
<tr>
<td>Primary or recurrence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary</td>
<td>109</td>
<td>1.72±0.29</td>
<td>&lt;0.05</td>
<td>13</td>
<td>73</td>
</tr>
<tr>
<td>Recurrence</td>
<td>47</td>
<td>3.68±0.41</td>
<td>&lt;0.05</td>
<td>2</td>
<td>4</td>
</tr>
</tbody>
</table>

Figure 1. FLOT1 protein expression by immunohistochemical staining. (A) FLOT1 expression (-), (B) weakly positive FLOT1 expression (+), (C) moderately positive FLOT1 expression (++), and (D) strongly positive FLOT1 expression (+++). Original magnification, x200.
FLOT1 enhances the adhesion, migration and invasion of TCC cells. The recurrence of TCC is related to spread by intraluminal seeding. Recurrence, a major cause of mortality in tumor patients, is a complex multistep process that includes cells adhesion, migration and invasion (25). The effects of FLOT1 on the adhesion, migration and invasion of TCC cells were evaluated in the present study. The expression of FLOT1 in 4 TCC cell lines was decreased by siRNA, and FLOT1 expression was increased by transfection with an expression pcDEF3 vector containing full-length cDNA. Protein expression was evaluated using western blot analysis (Fig. 3A). As shown in Fig. 3, TCC cells with high expression of FLOT1 had higher levels of adhesion (Fig. 4A), migration (Fig. 4B) and invasion (Fig. 4C) compared to untreated control cells. In contrast, TCC cells with low levels of FLOT1 due to siRNA treatment had significantly reduced adhesion (Fig. 4A), migration (Fig. 4B) and invasion (Fig. 4C) when compared to untreated control cells. These results suggest that FLOT1 can increase the adhesion, migration and invasion of TCC cells, and that FLOT1 may have an important role in TCC recurrence.

Discussion

Bladder TCC is the 9th most common carcinoma in humans, and the incidence is nearly 3-fold higher in males than in females (26). TCC is a life-threatening disease due to the high rate of recurrence; radical cystectomy is the recommended treatment for muscle-invasive and recurrence-frequent disease. To prevent recurrence of TCC after transurethral resection, routine intravesical instillation with chemotherapeutic agents is usually performed (27). Although TCC is chemosensitive, no drugs are currently available to specifically block recurrence (28,29). Thus, a novel mechanism and therapeutic innovation for treating patients with recurrent TCC is urgently required.

Recently, FLOT1 was thought to be an oncogene in tumorigenesis; high expression of FLOT1 has also been detected in various human cancers. A study reported that FLOT1 was transfected stably into TCC cell lines. FLOT1 expression was also decreased using RNAi. (A) All transfections were confirmed by western blot analysis. The proliferative ability of TCC cells in vitro was evaluated by the WST-1 assay (B), and in vivo by an animal xenograft model with BALB/C nude mice (C).
Although the potential oncogenic role of FLOT1 has been shown in prostate carcinoma (24), the function of FLOT1 in TCC remains unclear, and the effects and mechanisms of FLOT1 on TCC proliferation need to be further elucidated. This is the first study involving FLOT1 in human TCC. In the present study, we examined the expression of FLOT1 in human TCC and the results indicated that FLOT1 expression is significantly overexpressed in TCC compared to normal urothelial tissues, as shown by immunohistochemistry. Moreover, FLOT1 expression was significantly related to tumor size, pathologic grade, clinical stage and recurrence. FLOT1 expression in TCC was detected by real-time PCR, RT-PCR and western blot analysis, and the results were confirmed by immunohistochemistry. We further investigated the effect of FLOT1 on the proliferation of TCC cells, and showed that high expression of FLOT1 significantly increased the proliferation of TCC cells in vitro, and in vivo in a xenograft model with BALB/C nude mice. Collectively, these findings indicated that FLOT1 is a key gene in tumorigenesis and plays an important role in the progression of TCC.

Attempts have been made to predict recurrences in patients with TCCs; however, the mechanism underlying recurrence remains obscure (32-34). Since FLOT1 acts as an important gene in various biological behaviors, such as cell adhesion and invasion, a study suggested that FLOT1 can enhance cell invasion by increasing NF-κB activation in esophageal squamous cell carcinoma cells (22). Therefore, we speculate that FLOT1 may participate in TCC recurrence. It has been reported that the recurrence of TCC is closely associated with spread by intraluminal seeding (35), and recurrence is a complex multistep process that includes adhesion, migration and invasion of tumor cells (36). Thus, the effects of FLOT1 on adhesion, migration and invasion of TCC cells were analyzed in the present study. Our data indicate that FLOT1 enhances the adhesion, migration and invasion potential of TCC. Moreover, FLOT1 is overexpressed in recurrent TCC compared to primary TCC based on real-time PCR and immunohistochemistry. These results suggest that FLOT1 prompts the adhesion, migration and invasion of TCC cells and leads to recurrent TCC.

In conclusion, our results indicated that FLOT1 expression is upregulated in human TCC and high expression of FLOT1 might lead to progression and recurrence of TCC. It is also possible that patients with high levels of FLOT1 expression may be vulnerable to the progression of TCC and FLOT1 may be a useful marker for recurrent TCC. Our findings suggest that FLOT1 plays an important role in the proliferation and recurrence of TCC and silencing FLOT1 expression may prove to be a novel therapeutic strategy. The detailed molecular mechanisms by which FLOT1 determines TCC characteristics warrant further investigation.

References


